Enlivex Ltd. (ENLV) Form 6-K — Oct 19, 2026
Enlivex announced an immediate cost reduction plan on October 19, 2026, designed to substantially cut cash burn and focus resources on its Phase 2b trial of Allocetra™ in moderate-to-severe age-related knee osteoarthritis. The plan includes winding down all non-clinical R&D, a workforce reduction of approximately 60%, a 20% salary cut for management, and a 40% salary cut for CEO Oren Hershkovitz. The company expects topline six-month data from the Phase 2b trial by mid-2027, building on positive Phase 1/2a results and FDA RMAT designation granted in July 2026.
Key figures
- Phase 2b topline data
- mid-2027
- Workforce reduction percent
- approximately 60%
- Ceo salary reduction percent
- 40
- Management salary reduction percent
- 20
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.